Dental Care Clinics in Trophy Club, TX Accepting Medicare
6 Dental Care Clinics found. Showing 1 - 6
 Trophy Smile Studio Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 301 Trophy Lake Dr, # 120, Trophy Club, TX 76262 Phone: 817-778-0337 Fax: 817-720-0038 |
Dr Alexander Wenner Pllc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 2240 E Highway 114 Ste 650, Trophy Club, TX 76262 Phone: 817-532-5153 Fax: 817-984-8404 |
Summit Dental Care Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2001 E Highway 114, Suite 170, Trophy Club, TX 76262 Phone: 817-359-3800 |
David Crumpton Dds Pa Dentist Medicare: Not Enrolled in Medicare Practice Location: 301 Trophy Branch Dr Ste 100, Trophy Club, TX 76262 Phone: 817-691-8379 |
Trophy Dental Pa Dentist Medicare: Not Enrolled in Medicare Practice Location: 301 Trophy Lake Dr, Ste 120, Trophy Club, TX 76262 Phone: 817-854-0360 Fax: 817-490-9029 |
Bella Vita Dentistry Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 925 Trophy Club Dr, Trophy Club, TX 76262 Phone: 817-345-6960 |
News Archive
Inovalon, Walgreens sign agreement to bring innovative solutions to healthcare marketplace
Inovalon, Inc., a leading provider of data-driven healthcare solutions, and Walgreens, the nation's largest drugstore chain, today announced that they have entered into a multi-year agreement to provide Inovalon's data-driven encounter support platform, Electronic Patient Assessment Solution Suite within Healthcare Clinic at select Walgreens to support improvements in managed care quality and performance.
Designer enzymes
Chemists from UCLA and the University of Washington have succeeded in creating "designer enzymes," a major milestone in computational chemistry and protein engineering.
Gastrointestinal hormone offers possible new treatment for NAFLD and NASH patients
Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.
› Verified 3 days ago